The SM pathogenesis driven by KIT mutations led to exploring the potential utility of TKIs, but the evidence of resistance to the first-generation TKI imatinib in D816V-positive cases induced the development of new highly selective TKIs. Here, KIT is linked to systemic mastocytosis.